Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Inclusion Criteria: * Male or female, ≥18 y of age * Judged to be in generally good health * Fasting triglycerides ≥150 mg/dL to ≤499 mg/dL during screening * Body mass index of ≥20.0 kg/m2 * No clinically significant findings in a 12-lead ECG or physical examination * Willing and able to undergo the scheduled study procedures * Understands study procedures and signs forms documenting informed consent to participate in the study Exclusion Criteria: * Laboratory test result of clinical significance * Uncontrolled hypertension * Clinically significant gastrointestinal, endocrine, cardiovascular, renal, hepatic, pulmonary, pancreatic, neurologic, or biliary disorder * History of human immunodeficiency virus, hepatitis B or hepatitis C infection * Used any medication intended to alter the lipid profile within 4 weeks of the first qualification visit * Active systemic infection * A condition the Investigator believes would interfere subject ability to provide informed consent and/or comply with the study protocol